Literature DB >> 4067257

Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis.

J C Barbare, R E Poupon, P Jaillon, S Prod'homme, F Darnis, R Y Poupon.   

Abstract

Child-Turcotte classification (CTC) is an empirical but widely accepted approach for assessment of severity of cirrhosis. However, it is not known to what extent CTC reflects accurately the degree of impairment of hepatic function. In this study we compared CTC, standard liver tests and intrinsic hepatic clearance (IHC) of indocyanine green as means of assessing hepatic function in 63 cirrhotic patients. As compared to 10 control patients, IHC was significantly decreased in the cirrhotic group: (mean +/- SD) 0.270 +/- 0.141 l/min vs 1.227 +/- 0.312 l/min (P less than 0.001). Serum bilirubin (SB), prothrombin time (PT) and serum albumin were significantly correlated with the degree of IHC impairment while alkaline phosphatase, ALAT and clinical criteria of CTC were not. Multivariate analysis showed that SB and PT were the only 2 variables that significantly explained the impairment of IHC. The model which best explained IHC impairment was Z = 21.77 + 4.78 PT - 1.25 SB. The rate of IHC variance explained by this model, as determined by multiple correlation coefficient square (R2), was 42.6%. These results suggest that CTC provides only gross information about the degree of impairment of liver function in cirrhosis. To evaluate the role of liver function in the prognosis or in the response to treatments, it should therefore be preferable to employ direct measurement of liver function using a clearance technique.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4067257     DOI: 10.1016/s0168-8278(85)80053-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 2.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 3.  Effects of liver disease on pharmacokinetics. An update.

Authors:  V Rodighiero
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

4.  Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C.

Authors:  C Herold; P Berg; D Kupfal; D Becker; D Schuppan; E G Hahn; H T Schneider
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

5.  Discrimination of liver cirrhosis from chronic hepatitis by analysis of serum cholinesterase isozymes using affinity electrophoresis with concanavalin A or wheat germ agglutinin.

Authors:  T Hada; T Ohue; H Imanishi; H Nakaoka; A Hirosaki; S Shimomura; M Fujikura; Y Matsuda; T Yamamoto; Y Amuro
Journal:  Gastroenterol Jpn       Date:  1990-12

Review 6.  Antiarrhythmics: elimination and dosage considerations in hepatic impairment.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

8.  Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases.

Authors:  S Esposito; D Galante; D Barba; W Bianchi; R Gagliardi; R Giusti
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results.

Authors:  J M Rodríguez-Laiz; R Bañares; A Echenagusia; M Casado; F Camuñez; F Pérez-Roldán; A de Diego; E Cos; G Clemente
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Measurement of functioning hepatocyte mass via [99mTc]galactosyl-neoglycoalbumin.

Authors:  M Kudo; D R Vera; R C Stadalnik; C O Esquivel; W L Trudeau; K Ikekubo; A Todo
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.